Napredna pretraga

Pregled bibliografske jedinice broj: 745120

Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys


Hauser, Goran; Milošević, Marko; Giljača, Vanja; Benjak, Indira; Bulić, Zlatko; Štimac, Davor
Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys // Combined EPC & IAP Meeting
Southhampton, Velika Britanija, 2014. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Diclophenac potassium versus cephtazidime for reduction of post ERCP pancreatitis in average risk patients-randomised controlled trial- interim analysys

Autori
Hauser, Goran ; Milošević, Marko ; Giljača, Vanja ; Benjak, Indira ; Bulić, Zlatko ; Štimac, Davor

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
Combined EPC & IAP Meeting

Mjesto i datum
Southhampton, Velika Britanija, 24.-28.06.2014

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Acute pancreatitis; ERCP

Sažetak
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common major complication of ERCP. In some cases pancreatitis is followed by severe course with pancreatic necrosis and multiorgan failure. Diclophenac potassium together with indometacine is currently standard treatment in prevention of PEP while ceftazidime is possible alternative treatment for patients with contraindication for nonsteroidal antiimflammatory drugs (NSAID).

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka